GTHX Tiesioginiai signalai | Didinkite pelną su Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 birž. 2024 @ 23:00):
Our systems believe the stock currently is undervalued by -0.29% compare to its pairs and should correct upwards.

Stats
Šios dienos apimtis	602 599
Vidutinė apimtis	1.33M
Rinkos kapitalizacija	139.59M
EPS	$-0.200 ( Q1 \| 2024-05-01 )
Kita pelno data	( $0 ) 2024-07-31
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-4.45 (Sector) 42.63 (Industry) 24.32
ATR14	$0.00700 (0.26%)

AADI -3.55%

ABCL -5.26%

ABCM 0.04%

ABEO -1.31%

ABIO -1.53%

ABOS -5.30%

ABSI -14.32%

ABUS -2.55%

ABVX -0.22%

ACAD -0.47%

ACER -17.95%

ACET -2.22%

ACGN 1.29%

ACHL 0.23%

ACHV 1.63%

ACIU -4.23%

ACLX -1.21%

ACRV -5.10%

ACST 0.62%

ACXP -0.42%

ADAG -5.64%

ADAP -7.23%

ADGI 0.87%

ADIL -2.29%

ADMA -1.79%

ADPT 0.32%

ADTX -7.69%

ADVM -3.94%

ADXN -6.11%

AEON 11.51%

AEZS -5.44%

AFMD -5.07%

AGEN -7.50%

AGIO -3.45%

AGLE 6.66%

AGTC 0.00%

AIKI 0.85%

AIMDW 53.45%

AKBA -1.87%

AKRO -4.46%

AKTX -6.33%

AKUS 0.00%

ALBO 0.00%

ALDX -1.34%

ALEC -2.35%

ALGS -5.76%

ALKS 2.08%

ALLK 0.86%

ALLO -2.13%

ALLR -3.01%

ALNA 3.16%

ALNY -1.93%

ALPN 0.00%

ALPX 0.00%

ALRN -0.31%

ALT -3.11%

ALVR -4.43%

ALXN 0.00%

ALXO -8.32%

ALZN -12.01%

AMRN -2.58%

AMTI -3.13%

ANAB -1.64%

ANEB -5.58%

ANGN 0.00%

ANIX -0.38%

ANL 0.61%

ANNX -4.63%

ANPC -3.15%

APGE -5.23%

APGN 8.48%

APGNW 30.65%

APLM -4.73%

APLS -3.98%

APLT -4.36%

APM 1.33%

APOP 0.38%

APRE 2.44%

APTO -3.96%

APTX 3.17%

APVO -20.53%

ARAV -13.39%

ARCT -9.26%

ARDS 20.48%

ARDX -0.94%

ARGX -2.25%

ARNA 0.00%

ARPO -0.90%

ARQT -7.76%

ARTL -0.38%

ARTLW 9.80%

ARVN -2.84%

ARWR -2.86%

ASLN -12.17%

ASMB -1.49%

ASND -2.39%

ATAI -2.19%

ATHA 2.36%

ATHE -1.61%

ATHX -33.50%

ATNF 15.09%

ATOS -4.17%

ATRA -16.93%

ATXI -1.66%

ATXS -3.50%

AUPH -1.95%

AURA 0.96%

AUTL -4.22%

AVBP -1.02%

AVEO 0.00%

AVIR -2.22%

AVRO 2.10%

AVTE -93.30%

AVTX 4.08%

AVXL -1.06%

AXLA 0.00%

AXSM 3.22%

AYLA 0.00%

AZRX 2.07%

BBI 2.17%

BBIO -2.26%

BCAB -1.89%

BCDA -2.05%

BCDAW -33.33%

BCEL -1.32%

BCLI -8.47%

BCRX 1.13%

BCTX 4.96%

BCTXW 0.00%

BCYC -4.33%

BDRX 1.89%

BDTX -8.38%

BEAM -3.38%

BFRA -2.91%

BGNE -1.97%

BIOR -10.12%

BIVI 0.41%

BLCM -6.68%

BLI -5.88%

BLPH -0.79%

BLRX -3.79%

BLTE -0.72%

BLU 0.03%

BLUE -0.77%

BMEA -9.75%

BMRN 1.81%

BNOX 1.64%

BNTC 2.46%

BNTX -3.95%

BOLD -5.95%

BOLT -0.82%

BPMC -1.59%

BPTH 10.65%

BPTS -13.47%

BRNS -6.63%

BRTX 20.00%

BTAI -2.92%

BTTX -7.50%

BTX 0.05%

BVXV 0.74%

BXRX 7.39%

BYSI 6.06%

CABA -12.20%

CADL -0.96%

CALA 60.00%

CALC -1.62%

CALT 0.03%

CAPR -4.06%

CARA -27.26%

CARM -9.65%

CASI -8.04%

CATB -6.97%

CBAY 0.03%

CBIO -2.65%

CBLI -7.31%

CBUS 3.07%

CCCC -5.48%

CCXI 0.00%

CDAK 0.00%

CDIO -1.51%

CDIOW -23.08%

CDMO 5.72%

CDMOP 0.04%

CDT -6.11%

CDTTW -47.71%

CDTX -6.32%

CDXC -0.67%

CDXS -2.30%

CELC -2.79%

CELU -2.19%

CELUW -9.52%

CERC -1.68%

CERE -0.16%

CERO -7.87%

CEROW -44.78%

CFRX -27.95%

CGEM 0.74%

CGEN -5.31%

CGON -2.68%

CGTX 0.92%

CHMA -6.00%

CHRS -2.96%

CINC 0.00%

CING -1.09%

CINGW -48.24%

CKPT -4.25%

CLBS -16.75%

CLDX 0.69%

CLGN 1.19%

CLLS -4.89%

CLNN -2.48%

CLNNW -41.25%

CLRB -9.94%

CLSD -0.84%

CLSN -0.68%

CLVS 0.00%

CMMB -24.79%

CMND 1.83%

CMPI 0.00%

CMPX 5.41%

CMRA 0.40%

CMRAW 33.33%

CMRX 1.44%

CNCE 0.00%

CNSP 3.94%

CNST 0.00%

CNTA -6.39%

CNTB 3.13%

CNTX -1.02%

COCP -0.16%

COEPW -0.66%

COGT 4.45%

CORT -1.31%

COYA -6.11%

CPRX -0.40%

CRBP -11.76%

CRBU -2.23%

CRDF -1.11%

CRGX -4.78%

CRIS 1.11%

CRNX -1.37%

CRSP -2.79%

CRTX 2.63%

CRVO -1.89%

CRVS -5.39%

CSBR 1.19%

CTCX -8.04%

CTIC 0.06%

CTMX -0.72%

CTNM 0.00%

CTXR -1.50%

CUE -1.47%

CVAC -5.18%

CVKD 3.18%

CWBR -2.55%

CYAD -12.96%

CYCC -3.55%

CYCCP -1.79%

CYCN 6.00%

CYT -2.27%

CYTK -2.13%

CYTO 2.48%

DARE -3.31%

DAWN -4.60%

DBTX -0.81%

DBVT 1.01%

DFFN 10.28%

DICE 0.06%

DMAC -0.42%

DNLI -1.21%

DNTH -2.85%

DOMH 1.99%

DRMA 0.00%

DRMAW 0.00%

DRNA 0.00%

DRTS -1.32%

DRTSW 1.01%

DRUG 0.00%

DSGN 2.97%

DTIL -2.07%

DYAI -5.29%

EARS -1.77%

EDIT 0.20%

EDSA 1.04%

EFTR -3.13%

EFTRW -0.26%

EIGR 0.00%

ELAB 1.44%

ELDN -6.93%

ELEV -7.89%

ELOX -12.50%

ELTX -2.33%

ELVN -0.65%

ELYM -13.05%

ENGN -3.89%

ENGNW -7.06%

ENLV -3.47%

ENOB 1.79%

ENSC -0.55%

ENTA -6.00%

ENTO -2.80%

ENTX 0.00%

ENVB -4.64%

EPIX -8.75%

EPRX -0.19%

EPZM 0.00%

EQ 0.50%

EQRX -2.09%

EQRXW 0.00%

ERAS -7.83%

ERNA 2.60%

ERYP 1.30%

ESLA -6.38%

ESLAW -9.25%

ETNB 1.03%

ETON -5.90%

ETTX 0.00%

EVAX -19.54%

EVGN -2.14%

EVLO 50.00%

EWTX -0.80%

EXAI 1.19%

EXEL 0.18%

EYEG -0.43%

EYEN 1.57%

EYPT -3.94%

FATE -1.11%

FBIO 1.60%

FBIOP -1.05%

FBLG -5.34%

FBRX -7.46%

FDMT 0.72%

FENC 0.74%

FGEN -5.36%

FHTX 9.52%

FIXX 0.77%

FMTX 0.00%

FNCH -6.25%

FOLD -0.99%

FREQ 4.76%

FRLN 0.15%

FRTX -0.54%

FSTX 0.00%

FTRE 0.38%

FULC -6.04%

FUSN 0.00%

FWBI 4.59%

FWP 0.00%

GALT -4.58%

GANX 6.45%

GBIO 6.57%

GBT 0.01%

GDTC 2.16%

GERN -4.11%

GHRS 3.42%

GLMD -6.66%

GLPG 1.18%

GLSI 18.16%

GLTO -4.90%

GLUE -4.18%

GLYC -9.70%

GMAB -1.57%

GMDA 0.00%

GMTX 0.00%

GNCA -85.71%

GNFT 0.14%

GNLX 1.27%

GNPX 1.84%

GNTA -0.60%

GOSS 0.02%

GOVX -7.50%

GOVXW -24.72%

GPCR 0.85%

GRAY -10.80%

GRCL 0.05%

GRNA -0.03%

GRNAW 8.91%

GRPH -2.75%

GRTS -2.71%

GRTX -4.26%

GTHX -3.96%

GUTS -3.90%

GXGXW 41.67%

GYRE 4.44%

HALO 0.32%

HARP 0.09%

HCWB -9.73%

HEPA -6.36%

HGEN -84.62%

HILS 5.66%

HLVX 1.33%

HOOK -4.04%

HOTH -3.73%

HOWL 3.99%

HRMY 1.10%

HRTX -10.42%

HSTO 62.16%

HUMA -12.20%

HUMAW -5.97%

IBRX -2.18%

ICCC 2.84%

ICPT 0.21%

ICU 1.30%

ICUCW -10.39%

ICVX -0.91%

IDRA -23.04%

IDYA -1.44%

IFRX -3.21%

IGMS 0.41%

IKNA -0.57%

IKT 8.90%

IMAB -1.09%

IMCR -3.82%

IMGN 0.02%

IMGO 0.00%

IMMP -0.74%

IMMX -0.49%

IMNM -11.86%

IMNN -1.80%

IMPL -27.27%

IMRA 15.96%

IMRN -2.78%

IMRX 1.66%

IMTX -0.08%

IMTXW -2.70%

IMUX -4.20%

IMV 0.00%

IMVT 3.08%

INAB -8.26%

INBX -9.62%

INCY 0.93%

INDP 7.98%

INFI -52.38%

INKT -1.05%

INM -2.58%

INMB -2.47%

INO -1.65%

INSM 1.22%

INTS -5.63%

INVA 1.57%

INZY -2.95%

IOBT -6.11%

IONS 0.27%

IOVA -0.98%

IPA 0.48%

IPHA -10.64%

IPSC 0.64%

IRON -3.05%

ISEE 0.38%

ITOS -6.04%

ITRM -1.74%

IVA -10.10%

IVVD -6.96%

JAGX -6.67%

JANX -4.57%

JAZZ 1.43%

JNCE 0.00%

JSPR -2.80%

JSPRW 2.33%

JUNS 0.00%

JUNSW 0%

KA 4.11%

KALV -2.07%

KDNY 0.22%

KMPH -0.34%

KNSA -1.28%

KNTE -0.38%

KOD -4.27%

KPRX -21.08%

KPTI 1.69%

KRBP 4.17%

KRON -3.70%

KROS -9.68%

KRRO -16.54%

KRTX 0.03%

KRYS -0.04%

KTRA -2.35%

KTTA -2.85%

KTTAW 8.62%

KURA -0.62%

KYMR -4.42%

KYTX -17.21%

KZIA -1.29%

KZR -2.71%

LABP 0.57%

LBPH 1.67%

LBPS 0.00%

LBPSW 14.81%

LEGN -2.24%

LENZ -0.54%

LEXX -5.18%

LEXXW -9.42%

LGND 0.72%

LGNDV 0.00%

LGVN -24.76%

LIAN 0.00%

LIFE 2.70%

LIPO -1.23%

LIXT 0.40%

LIXTW 27.74%

LJPC -0.32%

LMNL 0.12%

LOGC 2.76%

LPCN 12.64%

LPTX -1.90%

LQDA 3.01%

LRMR -14.91%

LSTA -4.97%

LTRN -8.57%

LUMO -2.95%

LVTX -9.52%

LXEO -6.50%

LXRX -5.49%

LYEL -8.05%

LYRA -8.37%

MACK 0.00%

MBIO 476.92%

MBRX -4.83%

MCRB -5.28%

MDGL -0.31%

MDNA -13.16%

MDWD 1.00%

MDXG 0.59%

MEIP 1.41%

MESO -0.55%

MGNX -4.03%

MGTA -7.74%

MGTX -2.23%

MGX -24.14%

MIRM 27.31%

MIRO 0.59%

MIST -1.42%

MITO 0.00%

MLEC -4.55%

MLECW 9.20%

MLND -5.36%

MLTX -2.99%

MLYS -3.02%

MNKD -1.04%

MNMD -3.36%

MNOV 0.00%

MNPR -8.51%

MOLN 8.81%

MOR 0.88%

MORF -1.25%

MREO 0.00%

MRKR 16.59%

MRNA -1.52%

MRNS -1.02%

MRSN -1.45%

MRTX -0.17%

MRUS -1.38%

MRVI -3.99%

MTCR -1.29%

MTEM 1.54%

MTP -18.50%

MURA 2.17%

MYMD 4.19%

NAMS -7.03%

NAMSW -7.61%

NAUT 0.00%

NBRV 0.71%

NBSE -1.56%

NBTX 4.77%

NCNA -1.64%

NERV 8.96%

NEXI 0.00%

NGM -1.28%

NGNE -6.08%

NKGN -4.44%

NKGNW 39.76%

NKTR 0.00%

NKTX -5.66%

NLSP 30.09%

NLSPW -16.67%

NMRA -4.09%

NMTR -42.97%

NOVN -24.84%

NRBO 0.45%

NRIX 0.72%

NRSN -3.82%

NRSNW 6.50%

NRXP 0.99%

NRXPW -15.65%

NRXS -6.06%

NTBL 13.82%

NTEC -12.45%

NTHI 0%

NTLA 0.08%

NTRBW -6.25%

NUVL -0.77%

NVAX -2.43%

NVCT 1.18%

NVIV -34.28%

NXTC -10.63%

NYMX -0.05%

OABI 0.95%

OABIW 13.46%

OBIO 0.88%

OBSV 0.00%

OCEA 10.64%

OCGN -5.63%

OCS -1.09%

OCUL -4.35%

OCUP 1.82%

ODT -4.27%

OKYO 0.00%

OLMA -3.96%

OMER -0.49%

OMGA -8.37%

ONCO 12.54%

ONCR -3.08%

ONCS 31.87%

ONCT -0.12%

ONCY -0.98%

ONTX -0.47%

ONVO 0.62%

OPNT 0.00%

OPT -5.51%

ORGS -1.72%

ORIC -0.67%

ORMP -0.44%

ORPH 0.00%

ORTX 0.30%

OSMT -1.77%

OTIC -92.64%

OTLK -1.43%

OVID -76.00%

OYST 0.00%

PALI 0.86%

PASG -3.81%

PBLA 9.76%

PBM -0.02%

PBYI 2.89%

PCSA 5.71%

PCVX -1.45%

PDSB -4.13%

PEPG 0.70%

PGEN 0.00%

PHAR 2.17%

PHAS 0.00%

PHAT 3.08%

PHIO 4.14%

PHIOW 36.47%

PHVS -0.53%

PHXM -5.20%

PIRS -5.64%

PKBO 0.00%

PKBOW 999 900.00%

PLRX -5.08%

PLUR 0.00%

PMN -5.59%

PMVP -1.20%

PNT 0.16%

PPBT -11.48%

PRAX -6.21%

PRDS 0.93%

PRLD 0.77%

PROG -3.47%

PROK 6.96%

PRQR -3.41%

PRTA -0.20%

PRTC -0.72%

PRTG -1.96%

PRTK 1.83%

PRVB 0.00%

PSTI -2.91%

PSTV 0.00%

PSTX 1.81%

PTCT -1.14%

PTE -0.82%

PTGX -2.76%

PTIXW 2.50%

PULM 3.72%

PXMD -1.92%

PYPD -0.36%

PYXS -3.43%

QLGN -11.72%

QNCX 0.00%

QNRX -10.97%

QSI -2.92%

QSIAW 0.00%

QTTB 3.82%

QURE -4.09%

RAIN -1.63%

RANI -5.46%

RAPT -0.30%

RARE 1.92%

RCKT -3.02%

REGN 0.85%

RENB -3.05%

REPL -6.63%

RETA 0.02%

REUN -0.89%

REVB 1.36%

REVBU 3.46%

REVBW 25.20%

RGLS -1.66%

RGNX -6.20%

RIGL -2.79%

RLAY -3.01%

RLMD -0.33%

RLYB -6.15%

RNA -0.10%

RNAC -14.55%

RNAZ -5.83%

RNXT 14.41%

ROIV 0.28%

ROIVW 4.56%

RPHM -0.60%

RPRX -1.15%

RPTX 0.00%

RUBY 2.70%

RVLP -32.05%

RVMD -3.94%

RVMDW -23.93%

RVNC -0.71%

RVPH -0.68%

RVPHW 11.54%

RXDX 0.09%

RXRX 1.19%

RYTM -3.76%

RYZB 0.02%

RZLT -2.53%

SABS 3.17%

SABSW -32.14%

SAGE -6.08%

SANA -1.32%

SAVA 0.81%

SAVAW 0.00%

SBBP 1.52%

SBTX 1.03%

SCNI 60.46%

SCPH -1.69%

SCPS 0.00%

SEEL -4.62%

SEER -3.37%

SELB -8.00%

SESN 7.29%

SGEN -0.07%

SGMO -17.30%

SGMT 1.93%

SGTX -2.56%

SIOX 22.63%

SLDB -5.44%

SLGL -2.22%

SLN -1.55%

SLNO 0.19%

SLRX 2.89%

SLS -16.67%

SMMT -5.84%

SNDX -1.14%

SNGX -5.91%

SNPX -3.97%

SONN -4.75%

SPPI -0.49%

SPRB 0.49%

SPRC -3.16%

SPRO -5.88%

SRNE 20.00%

SRPT -4.89%

SRRA 0.00%

SRRK -7.09%

SRZN -1.70%

STAB 0.00%

STOK -4.00%

STRO -7.51%

STSA 0.00%

STTK -19.55%

SURF -0.93%

SVRA -5.15%

SWTX -4.88%

SYBX -0.63%

SYRS -4.83%

TALS -0.73%

TARA -0.78%

TARS -6.91%

TBPH -0.59%

TCBP -8.64%

TCDA 0.00%

TCON 6.35%

TCRR 0.00%

TCRT 1.05%

TCRX -11.43%

TECH -1.40%

TENX -3.43%

TERN -2.93%

TFFP 0.52%

TGTX 0.12%

THRX 0.12%

TIL -2.06%

TLC 0.00%

TLSA 5.78%

TNGX 5.04%

TNXP -2.61%

TNYA -1.79%

TPST 0.34%

TRDA -3.61%

TRVI 2.08%

TRVN -1.88%

TSHA 1.51%

TSVT 3.29%

TTNP 1.45%

TVTX 2.23%

TYRA -8.69%

UBX -4.17%

UNCY 0.22%

URGN -4.79%

UTHR 3.12%

VACC 11.36%

VALN -1.55%

VAXX -0.11%

VBIV -3.61%

VBLT -8.77%

VCEL -1.37%

VCNX -3.70%

VCYT 1.96%

VERA -0.83%

VERU 2.29%

VERV -2.77%

VIGL -2.08%

VINC -4.90%

VIR -5.85%

VIRI 4.95%

VIRX -3.62%

VKTX 0.00%

VLON -13.04%

VNDA 1.76%

VOR 1.74%

VRCA 0.49%

VRDN -1.93%

VRNA 10.04%

VRPX 10.77%

VRTX -1.46%

VSTM 0.00%

VTGN -2.84%

VTVT -0.10%

VTYX -4.51%

VXRT -8.25%

VYGR -2.94%

VYNE 2.16%

VYNT 7.78%

WINT 7.98%

WVE -3.85%

XBIO 6.75%

XBIT -0.33%

XCUR -3.10%

XENE -1.75%

XERS -0.91%

XFOR -2.75%

XLO -6.86%

XLRN 0.00%

XNCR -5.15%

XOMA -4.31%

XOMAO 0.68%

XOMAP -0.14%

XRTX 1.96%

YMAB -1.34%

ZGNX 0.00%

ZIOP -0.88%

ZLAB 1.55%

ZNTL -5.09%

ZSAN 0.00%

Insider Trading

Date	Person	Action	Amount	type
2024-06-13	Sharpless Norman	Buy	30 000	Stock Options (Right to Buy)
2024-06-13	Sharpless Norman	Buy	10 000	Common Stock
2024-06-13	Secor Alicia	Buy	10 000	Common Stock
2024-06-13	Secor Alicia	Buy	30 000	Stock Options (Right to Buy)
2024-06-13	Muir Glenn P	Buy	10 000	Common Stock

INSIDER POWER
68.53
Last 100 transactions
Buy: 2 418 469 \| Sell: 419 046

Koreliacija (AI algo v.1.1b): Undervalued: -0.29% $2.65 paired level. (Algoritmas realiuoju laiku stebi didžiausią koreliaciją turinčių akcijų pokyčius ir suteikia momentinę informaciją)

Tūris Koreliacija

Ilgas: -0.10 (neutral)

Trumpas: -0.52 (weak negative)

Signal:(37.388) Neutral

G1 Therapeutics Inc Koreliacija

10 Labiausiai teigiamai susiję koreliacijos
VLYPP	0.843

10 Labiausiai neigiamai susiję koreliacijos

Ar žinojote?

Koreliacija yra statistinis rodiklis, aprašantis ryšį tarp dviejų kintamųjų. Jis svyruoja nuo -1 iki 1, kur -1 reiškia tobulo neigiamo ryšio koreliaciją (padidėjus vienam kintamajam, sumažėja kitas), 1 reiškia tobulo teigiamo ryšio koreliaciją (padidėjus vienam kintamajam, padidėja ir kitas), o 0 reiškia jokios koreliacijos (tarp kintamųjų nėra jokio ryšio).

Koreliacija gali būti naudojama analizuojant bet kurių dviejų kintamųjų ryšį, ne tik akcijų. Jis dažnai naudojamas finansų, ekonomikos, psichologijos ir kitose srityse.

G1 Therapeutics Inc Koreliacija - Valiuta/Žaliavos

-0.73
( moderate negative )

-0.66
( moderate negative )

0.00
( neutral )

0.52
( weak )

G1 Therapeutics Inc Finansinės ataskaitos

Annual	2023
Pajamos:	$82.51M
Bruto pelnas:	$75.32M (91.28 %)
EPS:	$-0.930

FY	2023
Pajamos:	$82.51M
Bruto pelnas:	$75.32M (91.28 %)
EPS:	$-0.930

FY	2022
Pajamos:	$51.30M
Bruto pelnas:	$47.55M (92.69 %)
EPS:	$-3.38

FY	2021
Pajamos:	$31.48M
Bruto pelnas:	$29.46M (93.60 %)
EPS:	$-3.50

Financial Reports:

No articles found.

G1 Therapeutics Inc Options Data

Calls

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

Puts

Contract Name	Last Trade Date (EDT)	Strike	Last Price	Bid	Ask	Change	% Change	Volume	Open Interest	Implied Volatility	Strike Date
No data available

G1 Therapeutics Inc

G1 Therapeutics, Inc., a clinical-stage biopharmaceutical company, engages in the discovery, development, and commercialization of small molecule therapeutics for the treatment of patients with cancer. The company offers COSELA, which helps to decrease chemotherapy-induced myelosuppression in adult patients when administered prior to a platinum/etoposide-containing regimen or topotecan-containing regimen for extensive stage small cell lung cancer. It is also developing trilaciclib, a (CDK) 4/6 inhibitor that is in Phase III clinical trials for patients with first line colorectal cancer; Phase III clinical trial for the treatment of first line triple negative breast cancer; Phase II clinical trial for patients with first line bladder cancer; Phase II clinical trial for patients with combination with the antibody-drug conjugate; and Phase II clinical trial for the treatment of neoadjuvant breast cancer. In addition, the company develops lerociclib, an oral CDK4/6 inhibitor for multiple oncology indications; and rintodestrant, an oral selective estrogen receptor degrader, which is in Phase IIa clinical trials for the treatment of estrogen receptor-positive and HER2-negative breast cancer. The company has a license agreement with EQRx, Inc. and Genor Biopharma Co. Inc. for the development and commercialization of lerociclib using an oral dosage form to treat any indication in humans, as well as Nanjing Simcere Dongyuan Pharmaceutical Co., LTD. for the development and commercialization of trilaciclib for any indication in humans through parenteral delivery, and ARC Therapeutics for the development and commercialization of a CDK2 inhibitor for all human and veterinary uses. G1 Therapeutics, Inc. was incorporated in 2008 and is headquartered in Research Triangle Park, North Carolina.